Evidence map›Paper›PMID 19958532›Full record

Trial reportCritical care (London, England)2009

Hemostasis during low molecular weight heparin anticoagulation for continuous venovenous hemofiltration: a randomized cross-over trial comparing two hemofiltration rates.

Heleen M Oudemans-van Straaten, Muriel van Schilfgaarde, Pascal J Molenaar, Jos Pj Wester, Anja Leyte

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Critical care (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00965328 (Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration), which is not on this map. Cited by 14 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 6 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00965328 phase4completednot on this map

Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration (CVVH), a Randomized Cross-over Trial Comparing Hemostasis Between Two Hemofiltration Rates

TypeinterventionalSponsorOnze Lieve Vrouwe GasthuisRan2007 to 2008Enrolled14ConditionsKidney, Acute Renal Failure, Multiple Organ FailureArmsCVVH 4 to 2 L/h, CVVH 2 to 4L/h
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 6 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Timing of kidney replacement therapy initiation for acute kidney injury.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Timing of renal replacement therapy initiation for acute kidney injury.The Cochrane database of systematic reviews · 2018
    Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Heleen M Oudemans-van StraatenDepartment of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, 1091 AC Amsterdam, The Netherlands. h.m.oudemans-vanstraaten@olvg.nl
Muriel van Schilfgaarde
Pascal J Molenaar
Jos Pj Wester
Anja Leyte
OLVG · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRenal insufficiency increases the half-life of low molecular weight heparins (LMWHs). Whether continuous venovenous hemofiltration (CVVH) removes LMWHs is unsettled. We studied hemostasis during nadroparin anticoagulation for CVVH, and explored the implication of the endogenous thrombin potential (ETP).

methodsThis cross-over study, performed in a 20-bed teaching hospital ICU, randomized non-surgical patients with acute kidney injury requiring nadroparin for CVVH to compare hemostasis between two doses of CVVH: filtrate flow was initiated at 4 L/h and converted to 2 L/h after 60 min in group 1, and vice versa in group 2. Patients received nadroparin 2850 IU i.v., followed by 380 IU/h continuously in the extracorporeal circuit. After baseline sampling, ultrafiltrate, arterial (art) and postfilter (PF) blood was taken for hemostatic markers after 1 h, and 15 min, 6 h, 12 h and 24 h after converting filtrate flow. We compared randomized groups, and 'early circuit clotting' to 'normal circuit life' groups.

resultsFourteen patients were randomized, seven to each group. Despite randomization, group 1 had higher SOFA scores (median 14 (IQR 11-15) versus 9 (IQR 5-9), p = 0.004). Anti-Xa art activity peaked upon nadroparin bolus and declined thereafter (p = 0.05). Anti-Xa PF did not change in time. Anti-Xa activity was not detected in ultrafiltrate. Medians of all anti-Xa samples were lower in group 1 (anti-Xa art 0.19 (0.12-0.37) vs. 0.31 (0.23-0.52), p = 0.02; anti-Xa PF 0.34 (0.25-0.44) vs. 0.51 (0.41-0.76), p = 0.005). After a steep decline, arterial ETPAUC tended to increase (p = 0.06), opposite to anti-Xa, while postfilter ETPAUC increased (p = 0.001). Median circuit life was 24.5 h (IQR 12-37 h). Patients with 'short circuit life' had longer baseline prothrombin time (PTT), activated thromboplastin time (aPTT), lower ETP, higher thrombin-antithrombin complexes (TAT) and higher SOFA scores; during CVVH, anti-Xa, and platelets were lower; PTT, aPTT, TAT and D-dimers were longer/higher and ETP was slower and depressed.

conclusionsWe found no accumulation and no removal of LMWH activity during CVVH. However, we found that early circuit clotting was associated with more severe organ failure, prior systemic thrombin generation with consumptive coagulopathy, heparin resistance and elevated extracorporeal thrombin generation. ETP integrates these complex effects on the capacity to form thrombin.

trial registrationClinicaltrials.gov ID NCT00965328.

Indexed as

Acute Kidney InjuryAdultAgedAnticoagulantsAPACHEBlood CoagulationCritical IllnessCross-Over StudiesFactor XaFemaleHemofiltrationHemostasisHeparin, Low-Molecular-WeightHumansMaleMiddle AgedAnticoagulantsFactor XaHeparin, Low-Molecular-WeightNadroparinThrombin

Identifiers

PMID19958532
PMCPMC2811918
OpenAlexW2118575683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.